Spath B, Hansen A, Bokemeyer C, Langer F. Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists. Platelets 2011 (in Druck)
2010
Robles-Carrillo L, Meyer T, Hatfield M, Desai H, Dávila M, Langer F, Amaya M, Garber E, Francis JL, Hsu YM, Amirkhosravi A. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol 2010; 185: 1577-83
Langer F, Holstein K, Eifrig B, Bokemeyer C. Tumor und Thrombose - Indikationen von niedermolekularem Heparin in der Onkologie und Hämatologie. Vasomed 2010; 22: 102-6
2009
Ingersoll SB, Langer F, Walker JM, Meyer T, Robson T, Amaya M, Desai H, Francis JL, Amirkhosravi A. Deficiencies in the CD40 and CD154 receptor-ligand system reduce experimental lung metastasis. Clin Exp Metastasis 2009; 26: 829-37
Haubold K, Rink M, Spath B, Friedrich M, Chun FKH, Marx G, Amirkhosravi A, Francis JL, Bokemeyer C, Eifrig B, Langer F. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009 (in Druck)
Langer F, Holstein K, Eifrig B, Bokemeyer C. Thromboembolische Komplikationen - Prophylaxe und Therapie im Fokus. Onkologe 2009; 15: 150-6
Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis JL, Amirkhosravi A. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009; 7: 171-81
2008
Langer F, Holstein K, Eifrig B, Bokemeyer C. Hämostaseologische Aspekte in der Onkologie. Hämostaseologie 2008; 28: 472-80
Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J, Brummendorf TH, Dierlamm J, Bokemeyer C, Eifrig B. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol 2008; 87: 451-7
Gerdsen F, Luxembourg B, Langer F, Bauersachs R, Lindhoff-Last E. A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin (LMWH), dalteparin. Blood Coagul Fibrinolysis 2008; 19: 477-81
2007
Langer F, Steinmetz O, Marx G, Amirkhosravi A, Eifrig B, Bokemeyer C, Brümmendorf TH. Aprotinin-associated hemolytic thrombotic microangiopathy in a patient with acute myelogenous leukemia (AML) and systemic coagulopathy. Am J Hematol 2007 (in Druck)
Langer F, Chun KHF, Amirkhosravi A, Friedrich M, Leuenroth S, Eifrig B, Bokemeyer C, Francis JL. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and association with hemostatic activation markers. Thromb Haemost 2007; 97: 464-70
2006
Langer F, Wintzer HO, Werner M, Weber C, Brummendorf TH, Bokemeyer C. A case of pulmonary carcinosarcoma (squamous cell carcinoma and osteosarcoma) treated with cisplatin and doxorubicin. Anticancer Res 2006; 26: 3893-7
Langer F, Amirkhosravi A, Ingersoll SB, Walker JM, Spath B, Eifrig B, Bokemeyer C, Francis JL. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost 2006; 4: 1056-62
2005
Gerdsen F, Weber M, Langer F, Eifrig B, Lindhoff-Last E. Platelet activation markers in patients with venous thromboembolism without predisposing factors. Pathophysiol Haemost Thromb 2005; 34: 1-5
Langer F, Ingersoll SB, Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, Walker JM, Amaya M, Desai H, Francis JL. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost 2005; 93: 1137-46
2004
Langer F, Amirkhosravi A, Loges S, Meyer T, Eifrig B, Hossfeld DK, Fiedler W, Francis JL. An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF. Thromb Haemost 2004; 92: 1136-46
2003
Willems M, Sterneck M, Langer F, Jung R, Haddad M, Hagel C, Kuetemeier R, Eifrig B, Broering D, Fischer L, Rogiers X. Recurrent deep vein thrombosis based on homozygous factor V Leiden mutation acquired after liver transplantation. Liver Transpl 2003; 9: 870-3
Weber M, Kroeger N, Langer F, Hansen A, Zabelina T, Eifrig B, Hossfeld DK, Zander AR. Non-overt disseminated intravascular coagulation in patients during treatment with anti-thymocyte globulin (ATG Fresenius®) for unrelated allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 817-22
2002
Langer F, Bergmann F, Budde U, Hegewisch-Becker S, Hossfeld DK. Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura. Br J Haematol 2002; 118: 271-4
Langer F, Eifrig B, Marx G, Stork A, Hegewisch-Becker S, Hossfeld DK. Exacerbation of antiphospholipid antibody syndrome after treatment of localized cancer: a report of two cases. Ann Hematol 2002; 81: 727-31
Eickhoff B, Jaehne M, Langer F. Extragonadal germ-cell tumor: a rare differential diagnosis of a cervical lump in a young man. Ear Nose Throat J 2002; 81: 580-2
1999
Langer F, Morys-Wortmann C, Küsters B, Storck J. Endothelial protease-activated receptor-2 induces tissue factor expression and von Willebrand factor release. Br J Haematol 1999; 105: 542-5
